Improving the evaluation of new cancer therapies to expedite patient access

改进新癌症疗法的评估以加快患者获得治疗的速度

• 批准号: nhmrc : 1128332
• 负责人: A/Pr Michael Coory
• 金额: $ 28.12万
• 依托单位: The University of Adelaide
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/improving-evaluation-new-patient-access/948190
• 关键词: Improving; evaluation; new; cancer; therapies

The government funds cancer drugs, but drugs have to provide value for money to Australian taxpayers. Most proposed cancer drugs provide a benefit to patients but reaching agreement on how much the government will pay for these drugs often delays access by months, and often over a year due to uncertainty regarding drugs’ long-term effects. This research will test methods and develop guidelines to reduce this uncertainty and provide earlier access to new cancer drugs.

政府资助抗癌药物，但药物必须为澳大利亚纳税人提供物有所值的服务。大多数拟议的癌症药物都能为患者带来好处，但由于药物长期效果的不确定性，就政府将为这些药物支付多少费用达成一致往往会延迟数月甚至一年以上。这项研究将测试方法并制定指南，以减少这种不确定性并提供更早获得新抗癌药物的机会。